131I-F16SIP

131I-F16SIP monoclonal antibody (radioimmunotherapy) · Philogen S.p.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 131I-F16SIP, covering 2014-02-25 to 2014-02-25. Get the full timeline:

Most recent: Clinical Trial Update: A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer [Phase 1, Phase 2]

See pricing